GRI Bio Inc（GRI）の財務GRIGRI Bio Inc

Evaluating the bottom line, GRI Bio Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -142.02%, provide a clear picture of how effectively GRI converts its operational activities into shareholder value.

In the context of the broader market, GRI competes directly with industry leaders such as APUS and NCNA. With a market capitalization of $4.07M, it holds a leading position in the sector. When comparing efficiency, GRI's gross margin of N/A stands against APUS's N/A and NCNA's N/A. Such benchmarking helps identify whether GRI Bio Inc is trading at a premium or discount relative to its financial performance.

The company reported a reduced net loss of approximately $2 million for Q1 2026, down from $3 million in Q1 2025, indicating improved cost control. Cash reserves increased to $11 million, providing better liquidity for operations.